IQVIA has welcomed Minister for Trade and Export Promotion, Baroness Rona Fairhead, to its UK HQ, following £44m Sector Deal announcements.
As part of the Second Life Sciences Sector Deal, IQVIA, facilitated by the National Institute for Health Research (NIHR), will open a fourth UK Prime Site to focus on clinical research across the North of England, including investing up to £24m over five years and plans to employ over 50 additional highly-skilled staff to drive additional trials across the UK.
The Northern Prime Site will include NHS research-ready hospitals across the Greater Manchester, Leeds and Sheffield region and embrace a data-enabled approach to the design and delivery of clinical trials and real-world evidence studies.
In addition, IQVIA will invest £20m over five years in a new partnership with Genomics England to develop services to allow authorised researchers to run studies enabling faster and more efficient drug research, and to develop more robust evidence to support treatment value and greater access to personalised medicines for NHS patients.
The announcement is a key development in IQVIA’s mission to drive healthcare forward through world-leading clinical trials and real-world evidence providing domain expertise, unparalleled data, transformative technology and advanced analytics including artificial intelligence.
Genomics England has also announced that the 100,000 Genomes Project has achieved its goal of sequencing 100,000 whole genomes from NHS patients.
Baroness Fairhead met IQVIA researchers, senior management and scientific staff as well as clinicians from clinical trials sites and research patients at the IQVIA London office. Speaking after her visit, she said: “IQVIA is a great example of a global company who are making the most of the fantastic environment for life sciences companies in the UK.
“Our higher education system and the access to world leading research and development facilities in the UK mean that companies have the ability to make innovative advancements that can change the lives of millions of people.
“I would encourage all businesses to make the most of the measures in the Government’s Life Sciences Sector Deal, as well as the offer set out in our Export Strategy as they look to expand their overseas operations.”
Tim Sheppard, Senior Vice President (SVP) and General Manager, Northern Europe IQVIA, said: “IQVIA believes in the UK’s potential to be a unique bioscience centre of excellence in life sciences, and this investment further supports the UK Government and the industry’s aim to ensure this potential is realised.
That centre of excellence status provides the opportunity to cement and extend our industry’s global leadership, developing a life sciences sector that can be truly world-leading. Vitally, this is also a platform from which we can build even greater sector momentum behind the overall UK Industrial Strategy.”
The Second Life Sciences Sector Deal is the extension of a previous set of deals announced alongside the UK’s Industrial Strategy in November 2017. Each deal represents a new strategic and long-term partnership with Government, backed by private sector co-investment and will drive investment in the UK’s world-leading research infrastructure and boost productivity in the sector.